

# Effect of five novel 5-substituted tetrandrine derivatives on P-glycoprotein-mediated inhibition and transport in Caco-2 cells

ZHONGLIAN CAO<sup>1</sup>, DAN LI<sup>1,2</sup>, LI LIU<sup>2</sup> and PING YANG<sup>1</sup>

<sup>1</sup>Instrumental Analysis Centre, School of Pharmacy, Fudan University, Shanghai 201203;

<sup>2</sup>Department of Pharmacology, Center for Pharmacological Evaluation and Research of SIPI, Shanghai Institute of Pharmaceutical Industry, Shanghai 200437, P.R. China

Received October 1, 2015; Accepted April 11, 2018

DOI: 10.3892/ol.2018.9492

**Abstract.** Tetrandrine (Tet) is a potent inhibitor that reverses P-glycoprotein-mediated multidrug resistance (MDR). A number of novel 5-substituted tetrandrine derivatives were synthesized by the authors. The present study aimed at identifying potential P-gp inhibitor candidates, and intracellular uptake and efflux experiments and Caco-2 cell-based Transwell transport studies were performed. It was demonstrated that all five test compounds were able to inhibit efflux and increase intracellular uptake of the P-gp substrate, rhodamine-123 (Rho-123); the test compounds were P-gp inhibitors. The trans-epithelial transport experiment indicated that the secretory (basolateral-to-apical) of Rho-123 decreased, the absorption (apical-to-basolateral) increased and the transport efflux ratio (ER) reduced in the presence of the five compounds. Among the compounds, fluobenzene-Tet (TF) exhibited similar inhibitory effect as Tet. Although the other four test compounds exhibited weaker inhibitory effects than Tet and TF, the compounds exhibited stronger inhibitory effects compared with the reference compound verapamil. The study demonstrated that the five novel 5-substituted tetrandrine derivatives are able to act as inhibitors of P-gp to overcome P-gp-mediated drug resistance.

## Introduction

Tetrandrine (Tet), a bisbenzylisoquinoline alkaloid isolated from the dried root of *Stephania tetrandra* S. Moore, exhibits broad pharmacological actions. Tet has potential either as a tumoricidal agent or as an adjunct to chemotherapy and radiotherapy (1). The potential of Tet to reverse ATP-binding cassette transporter activity had been previously demonstrated.

It has been indicated that the naturally occurring compound may be used as a chemosensitizer for treating P-glycoprotein (P-gp)-mediated cancer with multidrug resistance (MDR) (2). Selective alkylation substitution of Tet at the 5-position was systematically investigated, and a series of novel 5-substituted derivatives were prepared in the present study.

P-gp belongs to a family of ATP-binding cassette (ABC) transporters, and it is encoded by the MDR1 gene. The over-expression of MDR1 has been associated with chemotherapy failure in a number of types of cancer, including kidney, colon and liver cancer, as well as leukemia and lymphoma (3). The P-gp, membrane transporter protein, has a crucial role in the modulation of absorption, distribution, metabolism and excretion of drugs. P-gp is also known to function as a barrier protein to extrude toxins and xenobiotics from cells (4,5). P-gp is able to efflux various anticancer drugs out of the cells in order to decrease the intracellular accumulation of cytostatic drugs, including doxorubicin and paclitaxel (5). Therefore, the development of P-gp inhibitors, which are able to efficiently overcome MDR, is necessary (6). The P-gp inhibitors can either downregulate the expression of transporter proteins or have a synergistic effect with chemotherapeutic agents by inhibiting the efflux function of ABC transporters (7).

P-glycoprotein is overexpressed in the Caco-2 cell line. The Caco-2 cell line has a number of biophysical and biochemical characteristics, which are similar to the features of a normal intestinal absorptive cell. The Caco-2 cell line has become the most common and extensively characterized cell-based model in predicting the absorption and transport potential of compounds (8). Caco-2 cells also have been employed in several other studies that have investigated the mechanisms of transport, metabolism and the effect of P-glycoprotein on the efflux of compounds (8-12).

Caco-2 cell monolayers are usually cultured on semi-permeable plastic supports that may be fitted into the wells of multi-well culture plates. When cultured as a monolayer, Caco-2 cells differentiate to form tight junctions between cells to serve as a model of paracellular movement of compounds across the monolayer. The test compounds are added to either the apical or basolateral sides of the monolayer. Following incubation for various lengths of time, aliquots of the buffer in opposite chambers are removed in order to determine the concentration of test compounds. The rates of permeability for

---

Correspondence to: Dr Ping Yang, Instrumental Analysis Centre, School of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong, Shanghai 201203, P.R. China  
E-mail: yangping@fudan.edu.cn

**Key words:** novel 5-substituted tetrandrine derivatives, Caco-2, P-glycoprotein

each compound (apparent permeability coefficients) are then determined (13). The apparent permeability coefficient values obtained using Caco-2 cell monolayers are correlated with the *in vivo* absorption capability of the molecule (14-16).

The expression of P-gp may reduce the intracellular accumulation of Rhodamine-123 (Rho-123). Measuring the uptake or efflux of Rho-123 allows the characterization of cells with a MDR phenotype and P-gp overexpression even with low levels of resistance (17,18). Rho-123 is a substrate for P-glycoprotein (P-gp) and therefore can be used as a molecular probe for the investigation of the multidrug resistance (MDR) phenotype (19).

In the present study, the inhibition of P-gp and transepithelial transport properties in the presence of five novel 5-substituted tetrandrine derivatives in Caco-2 cells were studied. The Rho-123 uptake and efflux assay indicated that the five novel 5-substituted tetrandrine derivatives tested were able to inhibit efflux and increase the intracellular accumulation of Rho-123 in Caco-2 cells. Additionally, the 5-substituted tetrandrine derivatives were P-gp inhibitors. The analysis of transepithelial transport across Caco-2 cell monolayers indicated that the 5-substituted tetrandrine derivatives were able to increase the absorption and decrease the secretory transport of Rho-123 via the inhibition of P-gp-mediated drug efflux.

## Materials and methods

**Materials.** The Caco-2 cell line was obtained from the American Type Culture Collection (Manassas, VA, USA) at passage 17. Dulbecco's modified Eagle's medium (DMEM), non-essential amino acids (NEAA), fetal bovine serum (FBS), 0.25% trypsin/1 mM EDTA, antibiotic-antimycotic mixture (10,000 U/ml penicillin, 10,000 I/g/ml streptomycin) were purchased from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Dimethyl sulfoxide (DMSO), Rhodamine-123 (Rho-123), verapamil (VER) and MTT were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Tet was a gift from Dr Jiekai Cheng (Qinghai Ecion Pharmaceutical Co., Ltd., Xining, China), and novel 5-substituted Tet derivatives (purity, >98%) were synthesized by the lab of the authors of the present study. The 5-substituted tetrandrine derivatives were evaluated by chromatography, high-resolution electrospray ionization mass spectrometry (Table I and Fig. 1) and nuclear magnetic resonance spectroscopy. Chromatographic separation was performed on a waters Acquity UPLC HSS T3 column (2.1x100 mm, 1.7  $\mu$ m) by using the Agilent 1290 Series UHPLC system (Agilent Technologies, Inc., Santa Clara, CA, USA).

**Cell culture.** The Caco-2 cells were cultured in DMEM medium, which was supplemented with 10% FBS, 1% glutamine, 1% penicillin and streptomycin. In addition, 1% sodium pyruvate and 1% NEAA were added to the cell medium. In order to maintain a high P-glycoprotein 1 (P-gp) level, the cells were cultivated for 24 h in fresh culture medium (DMEM) with 2  $\mu$ g/ml doxorubicin (Selleck Chemicals, Houston, TX, USA). All cells were cultured at 37°C with 5% CO<sub>2</sub> and 95% humidified atmosphere. The experiments were performed with

cells in the logarithmic growth phase. The cells used for all the experiments were taken between passage number 30 and 50.

**Cytotoxicity of Caco-2 cells.** The viability of the Caco-2 cells was analyzed using the MTT assay as previously described (20). The cells (5x10<sup>4</sup> cells/well) were seeded in 96-well plates overnight. A series of concentrations of Tet (100, 200, 300, 400, 500, 600, 700, 800, 900 and 1,000  $\mu$ g/ml) were added and incubated for 24 h at 37°C. Subsequently, 100  $\mu$ l MTT (0.5 mg/ml) was added to each well following the removal of the culture medium and incubated for an additional 4 h at 37°C. Following the removal of the culture medium, the formed formazan was dissolved in 150  $\mu$ l DMSO. The plates were placed on a shaker for 5 min at room temperature, and optical density was measured using a microplate reader (M1000; Tecan Trading AG, Männedorf, Switzerland) at a wavelength of 570 nm. The IC<sub>50</sub> value was calculated by using Graphpad Prism software (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA).

**Determination of concentration and inhibition time of Rho-123 and Tet.** In order to determine the concentration of Rho-123, Caco-2 cells were incubated with a series of Rho-123 concentrations (0.1, 0.5, 1.0, 2.0, 5.0 and 10.0  $\mu$ g/ml) at 37°C for 1 h. The cells were analyzed with a flow cytometer (BD FACSAria; BD Biosciences, Franklin Lakes, NJ, USA) following digestion with trypsin. For the determination of the concentration of compounds, Caco-2 cells were incubated with a series of Tet concentrations (0, 1, 2 and 5  $\mu$ g/ml) at 37°C for 1 h, and then Rho-123 was added and the cells were incubated at 37°C for 1 h. The cells were subsequently analyzed by flow cytometry following trypsinization. For the determination of the duration of inhibition, Caco-2 cells were incubated with Rho-123 with different durations (0, 0.25, 0.5, 1, 2, 4 and 6 h). The cells were analyzed with a flow cytometer following digestion with trypsin. All experiments were analyzed independently for 3 times. The relative fluorescence intensity for each type of treatment was calculated as follows: % Inhibitory efficiency=(fluorescence intensity of test compound/VER) x100.

**Rho-123 uptake and efflux assay.** For the Rho-123 uptake assay, Caco-2 cells were seeded in 24-well plates. When confluent monolayers were formed, the cells were incubated with 5  $\mu$ g/ml Tet and its novel 5-substituted derivatives [tetrandrine-aromatic (TA), tetrandrine-toluene (TT), tetrandrine-pyridine (TP), tetrandrine-fluorobenzene (TF) and tetrandrine-trifluorobenzene (TTF); 5  $\mu$ g/ml; for 1 h. Subsequently, 5  $\mu$ M Rho-123 was added, and the cells were incubated at 37°C for 1 h following digestion with trypsin. The cells were analyzed by flow cytometry. For the Rho-123 efflux assay, Caco-2 cells were incubated with 5  $\mu$ M Rho-123 in the presence or absence of 5  $\mu$ g/ml test compounds at 37°C for 1 h. The cells were analyzed by flow cytometry after digestion with trypsin. In each independent experiment, 50  $\mu$ M VER (a known P-gp inhibitor) was used as a reference compound.

**Transepithelial transport across Caco-2 cell monolayers.** The transport of Rho-123 across Caco-2 cell monolayers in the presence or absence of Tet and novel 5-substituted

Table I. High-Resolution Mass Spectrometry data of tetrandrine and its novel 5-substituted derivatives (ESI-POS).

Compound name	Formula	Expected (m/z)	Found at (m/z)	Isotope difference (%)	Error (ppm)
Tet	C <sub>38</sub> H <sub>42</sub> N <sub>2</sub> O <sub>6</sub>	623.3116	623.3113	4.4	-0.4
TA	C <sub>44</sub> H <sub>46</sub> N <sub>2</sub> O <sub>6</sub>	699.3429	699.3423	13.7	-0.8
TT	C <sub>45</sub> H <sub>48</sub> N <sub>2</sub> O <sub>6</sub>	713.3585	713.3579	5.5	-0.9
TP	C <sub>43</sub> H <sub>45</sub> N <sub>3</sub> O <sub>6</sub>	700.3381	700.3385	3.6	0.6
TF	C <sub>44</sub> H <sub>45</sub> FN <sub>2</sub> O <sub>6</sub>	717.3334	717.3341	1.9	0.9
TTF	C <sub>45</sub> H <sub>45</sub> F <sub>3</sub> N <sub>2</sub> O <sub>6</sub>	767.3302	767.3308	1.9	0.7

Tet, tetrandrine; TA, tetrandrine-aromatic group; TT, tetrandrine-toluene; TP, tetrandrine-pyridine; TF, tetrandrine-fluobenzene; TTF, tetrandrine-trifluobenzene.




Figure 1. Molecular structure of tetrandrine and its novel 5-substituted derivatives. Tet, tetrandrine; TA, tetrandrine-aromatic group; TT, tetrandrine-toluene; TP, tetrandrine-pyridine; TF, tetrandrine-fluobenzene; TTF, tetrandrine-trifluobenzene.

tetrandrine derivatives (TA, TT, TP, TF and TTF) was investigated. The Caco-2 cell monolayers (between passage number 30 and 50) were cultured in a Transwell chamber. The integrity of the cell monolayers was evaluated prior to transport analysis by measuring transepithelial electrical resistance (TEER) using a Millicell ERS testing device (EMD Millipore, Billerica, MA, USA). The monolayers with >250 Ωcm<sup>2</sup> TEER were used for transport analysis. The transport experiments were conducted on day 21. The monolayers were treated by the compounds at a concentration of 5 μg/ml for 72 h. The monolayers were washed twice using PBS and then incubated in Hanks' balanced salt solution (HBSS buffer; pH 7.4; 25 mM HEPES and 25 mM glucose). Rho-123 (5 μM) was added on either the apical or basolateral side of the inserts. A total of 100 μl was withdrawn from the receiver chamber periodically for 30 min, and then was immediately replenished with an equal volume of pre-warmed HBSS. The transepithelial transport of Rho-123 across cell monolayers was determined by high-performance liquid chromatography (HPLC).

The apparent permeability coefficient (Papp) was calculated according to the following equation:  $P_{app} = (dQ/dt) / (A \times C_0)$ , where dQ/dt is the rate of appearance of drugs (Rho-123) on the acceptor side (mol/s), and A is the membrane surface area (0.33 cm<sup>2</sup>) of the Caco-2 monolayer, and C<sub>0</sub> is the initial drug (Rho-123) concentration on the donor side (mol/ml) (20).

The efflux ratio (ER) was determined by the following equations:  $ER = P_{app} (B \rightarrow A) / P_{app} (A \rightarrow B)$ , where the Papp (B→A) is the Papp in the secretory (B→A) direction, and

Papp (A→B) is Papp in the absorptive (A→B) direction. All results are presented as the mean ± standard deviation (n=3).

**HPLC analysis.** The samples for Rho-123 transport study were determined using the Waters 2695 HPLC system as previously described (21), which was equipped with a fluorescence detector. HPLC was performed at 488 nm (λ<sub>exc</sub>, 488 nm; λ<sub>em</sub>, 575 nm). The system was controlled using Empower 2 software (Waters Corporation, Milford, MA, USA). Chromatographic separation was performed on the XBridge™ C18 column (4.6x250 mm, 5 μm column). The column was kept at 25°C with a flow rate of 1 ml/min. The mobile phase consisted of methanol and water (50:50, v/v). The injection volume of the test sample was 20 μl.

**Statistics analysis.** All data sets were analyzed with GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). The results were expressed as the mean ± standard deviation. The comparisons were performed using Student's t-test (two-tailed) and one-way analysis of variance with post-hoc Dunnett's test. P<0.05 was considered to indicate a statistically significant difference.

## Results

**Cytotoxicity of Caco-2 cells.** As indicated in Fig. 2, the survival rate of Caco-2 cells was 100% at <100 μg/ml Tet. The IC<sub>50</sub> value was calculated using the GraphPad Prism 5.0 software. The IC<sub>50</sub> value was 240 μg/ml, which indicated that Tet exhibited no toxicity on Caco-2 cells at 0-100 μg/ml. Therefore, the concentrations for subsequent experiments were selected from 0-100 μg/ml.

**Determination of the concentration and duration of inhibition of Tet and Rho-123.** Prior to investigating the P-gp inhibitory activity and transepithelial transport properties, the concentration of Tet and Rho-123 and the inhibition time were determined. As indicated in Figs. 3-5, Caco-2 cells were incubated with a series of different concentrations of Tet and Rho-123 or for different periods of time (37°C). The cells were analyzed by flow cytometry. VER (50 μM) was used as a reference compound. All experiments were analyzed independently for 3 times. Based on the results of the assay, 5 μg/ml of each test compound and 2 μg/ml (5 μM) Rho-123 [the value




Figure 2. Cytotoxicity of tetrandrine on Caco-2 cells as assessed by MTT assay. The cells were incubated with a series of concentrations of Tet for 24 h. Subsequently, 100  $\mu$ l MTT (0.5 mg/ml) was added to each well following the removal of culture medium, and the cells were incubated for an additional 4 h. The formed formazan was dissolved in 150  $\mu$ l DMSO following the removal of culture medium. Absorbance at 570 nm was measured. The experiment was performed independently for three times.




Figure 3. Relative fluorescence intensity of different Rho-123 concentrations. Caco-2 cells were incubated with a series of concentrations of Rho-123 at 37°C, and then the cells were analysed with a flow cytometer. The experiment was performed independently for three times. Rho-123, rhodamine-123.

of Rho-123 used was the same as that used in a previous study (22)] were used in following experiments. Additionally, 1 h was used as the duration of inhibition.

**Rho-123 uptake and efflux assays.** The intracellular uptake and efflux of Rho-123 were evaluated in Caco-2 cells by flow cytometry. For the Rho-123 uptake assay, Caco-2 cells were incubated with 5  $\mu$ g/ml test compounds, and then the cells were incubated with 5  $\mu$ M Rho-123 for 1 h. The results indicated that the amount of Rho-123 in cells that were treated with the test compounds was significantly higher compared with the untreated control (Fig. 6A). Additionally, the findings indicated that the test compounds may increase the uptake of Rho-123. For the Rho-123 efflux assay, Caco-2 cells were incubated with 5  $\mu$ M Rho-123 in the presence or absence of 5  $\mu$ g/ml compounds for 1 h (Fig. 6B). The test compounds were able to inhibit the efflux of Rho-123.

**Trans epithelial transport of Rho-123 in Caco-2 cells that were treated in the presence or absence of test compounds.** The results are presented in Table II. The  $P_{app}$  values of Rho-123




Figure 4. Relative fluorescence intensity of Caco-2 cells following incubation with rhodamine-123 at different times. Caco-2 cells were incubated with Rho-123 with different durations at 37°C and then analysed with a flow cytometer. The experiment was performed independently for three times. \* $P < 0.05$  vs. control. Error bars represent the standard error of the mean value for three determinations.




Figure 5. Relative fluorescence intensity of rhodamine-123 in the presence of different tetrandrine concentrations. The cells were incubated with different concentrations at 37°C. The cells were analysed with a flow cytometer. VER (50  $\mu$ M) was used as a reference compound. The experiment was performed independently for three times. \*\*\* $P < 0.001$  vs. control. Error bars represent the standard error of the mean value for three determinations. VER, verapamil.

across Caco-2 cell monolayers were calculated (4). The value of  $P_{app}$  B $\rightarrow$ A (secretory) was  $7.32 \pm 0.82$  and  $P_{app}$  A $\rightarrow$ B (absorptive) was  $2.65 \pm 0.33$ . The value was well in the reported  $P_{app}$  value of  $1 \times 10^{-6}$  cm/s in Caco-2 cells, which is necessary for a compound to exhibit efficient absorption through the gastrointestinal epithelium (15).

**Basolateral to apical (B $\rightarrow$ A) transport.** The transport of Rho-123 in the B $\rightarrow$ A direction (secretory) across the monolayer was decreased in the presence of 5  $\mu$ g/ml TA, TT, TP, TF or TTF compared with cells that were not treated with the compounds. The value of  $P_{app}$  B $\rightarrow$ A was decreased from  $7.32 \pm 0.82$  to  $3.94 \pm 0.44$ ,  $4.18 \pm 0.39$ ,  $2.97 \pm 0.27$ ,  $2.34 \pm 0.21$  and  $2.83 \pm 0.25$ , respectively (Table II). The value of TF ( $2.34 \pm 0.21$ ) was lower compared with the value for Tet ( $2.38 \pm 0.24$ ). In the experiment, VER, the gold standard P-gp inhibitor (23), was used as a reference compound. The treatment of cells with VER led to a decrease in the secretion of Rho-123—from  $7.32 \pm 0.82$  to  $2.37 \pm 0.18$ . The value for VER was approaching






Figure 6. Intracellular uptake and efflux of Rho-123 in Caco-2 cells in the presence and absence of tetrandrine and its novel 5-substituted derivatives as analyzed by flow cytometry. (A) For the Rho-123 uptake assay, Caco-2 cells were incubated with 5  $\mu\text{g}/\text{ml}$  test compounds. Subsequently, 5  $\mu\text{M}$  Rho-123 was added and incubated with the cells for 1 h. (B) For the Rho-123 efflux assay, Caco-2 cells were incubated with 5  $\mu\text{M}$  Rho-123 in the presence or absence of 5  $\mu\text{g}/\text{ml}$  compounds for 1 h. The experiment was performed independently for three times. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  vs. control. Error bars represent the standard error of the mean value for three determinations. Tet, tetrandrine; TA, tetrandrine-aromatic group; TT, tetrandrine-toluene; TP, tetrandrine-pyridine; TF, tetrandrine-fluobenzene; TTF, tetrandrine-trifluobenzene; Rho-123, rhodamine-123; VER, verapamil.

the value for Tet ( $2.38 \pm 0.24$ ). The results indicated that 50  $\mu\text{M}$  VER had the same inhibitory effect as 8  $\mu\text{M}$  (5  $\mu\text{g}/\text{ml}$ ) Tet. In addition, TF had almost the same inhibitory effect as Tet. Although the other four test compounds had weaker inhibitory effects compared with Tet and TF, the effects of the four test compounds were stronger than VER. These findings demonstrated that these compounds (TA, TT, TP, TF and TTF) were P-gp inhibitors and exerted a strong inhibitory effect on the transport of Rho-123 across Caco-2 cells.

**Apical to basolateral (A $\rightarrow$ B) transport.** The transport of Rho-123 in the A $\rightarrow$ B direction (absorptive) across the monolayer was increased in the presence of 5  $\mu\text{g}/\text{ml}$  TA, TT, TP, TF or TTF compared with transport in the absence of these compounds.

The value of  $P_{\text{app}}$  A $\rightarrow$ B was increased from  $2.65 \pm 0.33$  to  $3.38 \pm 0.48$ ,  $2.73 \pm 0.18$ ,  $2.78 \pm 0.18$ ,  $3.04 \pm 0.31$  and  $2.80 \pm 0.20$ , respectively (Table II). The increase was 1.28-, 1.03-, 1.05-, 1.15- and 1.06-fold, respectively. The maximum increase (TA) in  $P_{\text{app}}$  for the test compounds (1.28-fold) was higher compared with the increase with Tet (1.20-fold) and VER (1.20-fold). It demonstrated that the absorption of Rho-123 was improved in the presence of the compounds.

**ER.** ER was determined by the equations:  $\text{ER} = P_{\text{app}}(\text{B} \rightarrow \text{A}) / P_{\text{app}}(\text{A} \rightarrow \text{B})$ , where the  $P_{\text{app}}(\text{B} \rightarrow \text{A})$  is the  $P_{\text{app}}$  in the secretory (B $\rightarrow$ A) direction,  $P_{\text{app}}(\text{A} \rightarrow \text{B})$  is  $P_{\text{app}}$  in the absorptive (A $\rightarrow$ B) direction. The presence of the 5 compounds did affect the transport ER of Rho-123; they all reduced the efflux of Rho-123. The value was significantly reduced from  $2.79 \pm 0.39$  to  $1.18 \pm 0.16$ ,  $1.54 \pm 0.15$ ,  $0.76 \pm 0.11$ ,  $1.07 \pm 0.09$  and  $1.01 \pm 0.11$  in the presence of TA, TT, TP, TF and TTF, respectively. The value of TF ( $0.78 \pm 0.10$ ) was approaching the value of Tet ( $0.76 \pm 0.11$ ; Table II).

## Discussion

Tet, a benzylisoquinoline alkaloid, is a potent inhibitor in reversal of P-gp-mediated MDR (24). There is an urgent

requirement for the development of strong inhibitors to overcome MDR. Consequently, five novel 5-substituted tetrandrine derivatives were synthesized in the present study.

In the present study, the inhibitory activity on P-gp and transepithelial transport experiments in the presence of the five compounds were performed by using P-gp-overexpressed Caco-2 cells. The results indicated that the five test compounds were P-gp inhibitors. The test compounds were not only able to increase the absorption but also decrease the secretory transport of Rho-123 via the inhibition of P-gp-mediated drug efflux. Among the test compounds, TF exhibited a similar extent of inhibitory effect as Tet.

P-gp was the first ABC transporter to be identified (25). The Caco-2 cell line with an overexpression of P-gp can be used to screen P-gp inhibitors and predict the absorption and transport potential of the test compounds. Rho-123 was selected as a representative P-gp substrate as its efficiency to combine with inhibitors for P-gp-mediated transport had been demonstrated in previous studies (26).

In the present study, the uptake and efflux of Rho-123 was quantified by flow cytometry in the presence or absence of the test compounds. By comparing the fluorescent intensity of Rho-123 in Caco-2 cells, the inhibitory effect of P-gp-mediated drug efflux was determined. The results showed that the five test compounds increased the intracellular uptake and decreased the Rho-123 efflux in Caco-2 cells.

In the transepithelial transport study, the Caco-2 cell monolayer was used for the assessment of absorption of drugs via the intestinal membrane enterocytes, which have been described in previous studies (9,14,27,28). A fully differentiated and tight monolayer was required for the permeability experiments. Differentiation also included the formation of tight junction between the cells. However, a monolayer that is too tight may underestimate the absorption of hydrophilic compounds that are not substrates for any absorptive transporters (29).

In the present study, the  $P_{\text{app}}$  value was calculated for Rho-123, which was well in the reported value of  $1 \times 10^{-6}$  cm/s in Caco-2 cells, which is necessary for a compound to exhibit efficient absorption through the gastrointestinal

Table II.  $P_{app}$  in A→B and B→A direction and efflux ratio (ER) of Rho-123 across Caco-2 cell monolayers treated in the presence or absence of tetrandrine and its novel 5-substituted derivatives.

Compounds	$P_{app}$ $10^{-6}$ (cm/s)		Efflux ratio
	B→A (secretory)	A→B (absorptive)	$P_{app}(B→A)/P_{app}(A→B)$
5 $\mu$ M Rho-123	7.32±0.82 <sup>f</sup>	2.65±0.33 <sup>c</sup>	2.79±0.39 <sup>f</sup>
5 $\mu$ M Rho-123 + 50 $\mu$ M VER	2.37±0.18 <sup>c</sup>	3.18±0.40 <sup>b</sup>	0.75±0.10 <sup>c</sup>
5 $\mu$ M Rho-123 + 5 $\mu$ g/ml Tet	2.38±0.24 <sup>c</sup>	3.19±0.37 <sup>b</sup>	0.76±0.11 <sup>c</sup>
5 $\mu$ M Rho-123 + 5 $\mu$ g/ml TA	3.94±0.44 <sup>c,f</sup>	3.38±0.48 <sup>c</sup>	1.18±0.16 <sup>c,f</sup>
5 $\mu$ M Rho-123 + 5 $\mu$ g/ml TT	4.18±0.39 <sup>c,f</sup>	2.73±0.18 <sup>d</sup>	1.54±0.15 <sup>c,f</sup>
5 $\mu$ M Rho-123 + 5 $\mu$ g/ml TP	2.97±0.27 <sup>c,f</sup>	2.78±0.18 <sup>d</sup>	1.07±0.09 <sup>c,e</sup>
5 $\mu$ M Rho-123 + 5 $\mu$ g/ml TF	2.34±0.21 <sup>c</sup>	3.04±0.31 <sup>a</sup>	0.78±0.10 <sup>c</sup>
5 $\mu$ M Rho-123 + 5 $\mu$ g/ml TTF	2.83±0.25 <sup>c,e</sup>	2.80±0.20 <sup>d</sup>	1.01±0.11 <sup>c,e</sup>

<sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ , <sup>c</sup> $P < 0.001$ , vs. Rho-123; <sup>d</sup> $P < 0.05$ , <sup>e</sup> $P < 0.01$ , <sup>f</sup> $P < 0.001$ , vs. Rho-123 + 5  $\mu$ g/ml Tet. Data are expressed as the mean  $\pm$  standard deviation of three independent experiments. Rho-123 was used at a concentration of 5  $\mu$ M, Tet and its novel 5-substituted derivatives were used at a concentration of 5  $\mu$ g/ml (equivalent to 8.0, 7.2, 7.0, 7.1, 7.0 and 6.5  $\mu$ M, respectively). VER was used at a concentration of 50  $\mu$ M. Tet, tetrandrine; TA, tetrandrine-aromatic group; TT, tetrandrine-toluene; TP, tetrandrine-pyridine; TF, tetrandrine-fluobenzene; TTF, tetrandrine-trifluobenzene; Rho-123, Rhodamine-123; VER, verapamil;  $P_{app}$ , apparent permeability coefficient.

epithelium (15). The transport of Rho-123 showed the ratio between two fluxes; from the basolateral to apical compartments (B→A, secretory, representative of passive diffusion) and from the apical to basolateral compartments (A→B, absorptive, representative of active transport). The transport of Rho-123 of B→A was significantly higher compared with A→B in the absence of these compounds. The B→A transport of Rho-123 was reduced and the A→B transport was increased in the presence of these compounds. These findings indicated that the compounds were not only able to increase absorption but also decrease the secretory transport of Rho-123.

These results confirmed that the combination of the test compounds with the P-gp substrate Rho-123 was able to increase uptake and absorption in the uptake assay and transport experiments. Furthermore, reductions in efflux and secretion were demonstrated with the test compounds, which supported the role of P-gp transporters in mediating the inhibitory effects of Rho-123.

In the present study, VER was used as a reference compound. VER is the gold standard P-gp inhibitor, and it had been demonstrated to inhibit P-gp (23). However, VER was indicated to be a relatively weak P-gp inhibitor compared with other P-gp inhibitors including cyclosporine A and Valspodar, and data from clinical trials regarding its efficacy had been disappointing (3,25). In the present study, 5  $\mu$ M Rho-123 was used. Tet and its novel 5-substituted derivatives were used at a concentration of 5  $\mu$ g/ml, which was equivalent to 8.0, 7.2, 7.0, 7.1, 7.0 and 6.5  $\mu$ M, respectively. VER was used at a concentration of 50  $\mu$ M.

It was indicated that 7.0  $\mu$ M TF (ER, 0.78±0.10) had almost the same extent of inhibitory effect as 50  $\mu$ M VER (ER, 0.75±0.10). In addition, 7.0  $\mu$ M TF exhibited a similar extent of inhibitory effect as 8.0  $\mu$ M Tet (0.76±0.11). Although the inhibitory effects of the four test compounds were weaker compared with Tet and TF, these test compounds were stronger than VER.

The findings in the present study demonstrated that these test compounds were P-gp inhibitors and exhibited P-gp-mediated inhibitory effects on the transport of Rho-123 across Caco-2 cells. Furthermore, the apparent permeability coefficient values obtained using Caco-2 cell monolayers are consistent with the *in vivo* absorption capability of the molecule (14-16). The use of the Caco-2 cell line model should enable the elucidation of P-gp-mediated transport and the overall membrane permeability of a P-gp substrate (30).

The results of the study indicated that the efflux function of P-gp was inhibited by the test compounds; the compounds were able to act as inhibitors of P-gp to decrease the secretion and increase the absorption of the P-gp substrate, Rho-123, across Caco-2 cell monolayers.

Although the five novel 5-substituted tetrandrine derivatives have been demonstrated to be able to act as inhibitors of P-gp to increase the absorption of drug, further studies are required to optimize the structure of the compounds to improve the inhibitory activity on P-gp. It was inferred that the P-gp inhibitory activity might be improved by using specific steric substituent, electro-donating and electro-withdrawing groups. Fluoride is a strong electro-withdrawing group (31), while the triple fluorine results in the weakness of electro-withdrawing group due to the steric hindrance and symmetry. Therefore, the 5-substituted tetrandrine derivatives, TF, exhibited stronger inhibitory effect on P-gp compared with TTF and TF exhibited similar inhibitory efflux effect as Tet. The lone-pair electrons nitrogenous compound, TP, had an electro-donating group, and TP had potential applications in improving the effect of P-gp to decrease the secretion and increase the absorption of drugs. Furthermore, several substituted groups with high lipid solubility might be utilized so that low-weight molecules can move more easily into the lipid bilayer and improve the inhibitory activity of the compounds on P-gp.

In summary, the molecular structural variations of Tet at 5-position provided good predictive information and would

be beneficial to the design of potent P-gp inhibitors. These findings would aid in understanding the structure design of tetrandrine derivatives and therefore support further structure optimization to develop novel P-gp inhibitors.

### Acknowledgements

The authors would like to thank Dr Jiekai Cheng of Qinghai Ecion Pharmaceutical Co., Ltd. for his research assistance.

### Funding

The present study was supported by the Shanghai Innovation Action Plan (grant no. 17DZ2203400).

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Authors' contributions

ZC and DL conducted the experiments. PY and LL conceived and designed the experiments. ZC analyzed the data. ZC wrote the manuscript.

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

- Chen YJ: Potential role of tetrandrine in cancer therapy. *Acta Pharmacol Sin* 23: 1102-1106, 2002.
- Zhu X, Sui M and Fan W: In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. *Anticancer Res* 25: 1953-1962, 2005.
- Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. *Nat Rev Cancer* 13: 714-726, 2013.
- Tang F, Ouyang H, Yang JZ and Borchardt RT: Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers. *J Pharm Sci* 93: 1185-1194, 2004.
- Oga EF, Sekine S, Shitara Y and Horie T: Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells. *Am J Trop Med Hyg* 87: 64-69, 2012.
- Dong X and Mumper RJ: Nanomedicinal strategies to treat multidrug-resistant tumors: Current progress. *Nanomedicine (Lond)* 5: 597-615, 2010.
- Liu KJ, He JH, Su XD, Sim HM, Xie JD, Chen XG, Wang F, Liang YJ, Singh S, Sodani K, *et al*: Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. *Int J Cancer* 132: 224-235, 2013.
- Hidalgo IJ, Raub TJ and Borchardt RT: Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. *Gastroenterology* 96: 736-749, 1989.
- Artursson P: Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. *J Pharm Sci* 79: 476-482, 1990.
- Wacher VJ, Silverman JA, Zhang Y and Benet LZ: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. *J Pharm Sci* 87: 1322-1330, 1998.
- Palm K, Luthman K, Ros J, Grasjo J and Artursson P: Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. *J Pharmacol Exp Ther* 291: 435-443, 1999.
- Raeissi SD, Hidalgo IJ, Segura-Aguilar J and Artursson P: Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. *Pharm Res* 16: 625-632, 1999.
- van Breemen RB and Li Y: Caco-2 cell permeability assays to measure drug absorption. *Expert Opin Drug Metab Toxicol* 1: 175-185, 2005.
- Artursson P and Karlsson J: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. *Biochem Biophys Res Commun* 175: 880-885, 1991.
- Yee S: In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. *Pharm Res* 14: 763-766, 1997.
- Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE and Grove JR: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. *J Pharm Sci* 88: 28-33, 1999.
- Canitrot Y and Lautier D: Use of rhodamine 123 for the detection of multidrug resistance. *Bull Cancer* 82: 687-697, 1995 (In French).
- Ludescher C, Gattringer, Drach J, Hofmann J and Grunicke H: Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine 123. *Blood* 78: 1385-1387, 1991.
- Twentyman PR, Rhodes T and Rayner S: A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. *Eur J Cancer* 30A: 1360-1369, 1994.
- Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J Immunol Methods* 65: 55-63, 1983.
- Cao Z, Li X, Liao X and Yang P: Development of an HPLC-FLD method for determination of rhodamine 123 in Caco-2 cell-based permeability studies. *Chromatographia* 79: 261-266, 2016.
- Mi Y and Lou L: ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. *Br J Cancer* 97: 934-940, 2007.
- Iqbal J, Hombach J, Matuszczak B and Bernkop-Schnurch A: Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. *J Control Release* 147: 62-69, 2010.
- Sun YF and Wink M: Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from *Stephania tetrandra* can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. *Phytomedicine* 21: 1110-1119, 2014.
- Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. *Cancer Cell Int* 5: 30, 2005.
- Foger F, Schmitz T and Bernkop-Schnurch A: In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. *Biomaterials* 27: 4250-4255, 2006.
- Artursson P: Cell cultures as models for drug absorption across the intestinal mucosa. *Crit Rev Ther Drug Carrier Syst* 8: 305-330, 1991.
- Rubas W, Cromwell ME, Shahrokh Z, Villagran J, Nguyen TN, Wellton M, Nguyen TH and Mrsny RJ: Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. *J Pharm Sci* 85: 165-169, 1996.
- Korjamo T, Honkakoski P, Toppinen MR, Niva S, Reinisalo M, Palmgrén JJ and Mönkkönen J: Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. *Eur J Pharm Sci* 26: 266-279, 2005.
- Doppenschmitt S, Spahn-Langguth H, Regardh CG and Langguth P: Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. *J Pharm Sci* 88: 1067-1072, 1999.
- Tajima T, Nakajima A and Fuchigami T: Electrolytic partial fluorination of organic compounds. 83. Anodic fluorination of N-substituted pyrroles and its synthetic applications to gem-difluorinated heterocyclic compounds. *J Org Chem* 71: 1436-1441, 2006.